Detalhe da pesquisa
1.
Molnupiravir for Oral Treatment of Covid-19 in Nonhospitalized Patients.
N Engl J Med
; 386(6): 509-520, 2022 02 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-34914868
2.
Clinical and microbiological outcomes, by causative pathogen, in the ASPECT-NP randomized, controlled, Phase 3 trial comparing ceftolozane/tazobactam and meropenem for treatment of hospital-acquired/ventilator-associated bacterial pneumonia.
J Antimicrob Chemother
; 77(4): 1166-1177, 2022 03 31.
Artigo
em Inglês
| MEDLINE | ID: mdl-35022730
3.
A Phase 3, Randomized, Double-Blind Study Comparing Tedizolid Phosphate and Linezolid for Treatment of Ventilated Gram-Positive Hospital-Acquired or Ventilator-Associated Bacterial Pneumonia.
Clin Infect Dis
; 73(3): e710-e718, 2021 08 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-33720350
4.
A Randomized, Double-blind, Multicenter Trial Comparing Efficacy and Safety of Imipenem/Cilastatin/Relebactam Versus Piperacillin/Tazobactam in Adults With Hospital-acquired or Ventilator-associated Bacterial Pneumonia (RESTORE-IMI 2 Study).
Clin Infect Dis
; 73(11): e4539-e4548, 2021 12 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-32785589
5.
Ceftolozane/tazobactam versus meropenem in patients with ventilated hospital-acquired bacterial pneumonia: subset analysis of the ASPECT-NP randomized, controlled phase 3 trial.
Crit Care
; 25(1): 290, 2021 08 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-34380538
6.
A Mortality Analysis of Letermovir Prophylaxis for Cytomegalovirus (CMV) in CMV-seropositive Recipients of Allogeneic Hematopoietic Cell Transplantation.
Clin Infect Dis
; 70(8): 1525-1533, 2020 04 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-31179485
7.
RESTORE-IMI 1: A Multicenter, Randomized, Double-blind Trial Comparing Efficacy and Safety of Imipenem/Relebactam vs Colistin Plus Imipenem in Patients With Imipenem-nonsusceptible Bacterial Infections.
Clin Infect Dis
; 70(9): 1799-1808, 2020 04 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-31400759
8.
Outcomes of patients with detectable CMV DNA at randomization in the phase III trial of letermovir for the prevention of CMV infection in allogeneic hematopoietic cell transplantation.
Am J Transplant
; 20(6): 1703-1711, 2020 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-31883426
9.
Comparison of Treatment Outcomes between Analysis Populations in the RESTORE-IMI 1 Phase 3 Trial of Imipenem-Cilastatin-Relebactam versus Colistin plus Imipenem-Cilastatin in Patients with Imipenem-Nonsusceptible Bacterial Infections.
Antimicrob Agents Chemother
; 64(5)2020 04 21.
Artigo
em Inglês
| MEDLINE | ID: mdl-32094127
10.
Impact of renal impairment and human organic anion transporter inhibition on pharmacokinetics, safety and tolerability of relebactam combined with imipenem and cilastatin.
Br J Clin Pharmacol
; 86(5): 944-957, 2020 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-31856304
11.
Pharmacokinetic Interactions between the Hepatitis C Virus Inhibitors Elbasvir and Grazoprevir and HIV Protease Inhibitors Ritonavir, Atazanavir, Lopinavir, and Darunavir in Healthy Volunteers.
Antimicrob Agents Chemother
; 63(4)2019 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-30745392
12.
Assessment of drug interaction potential between the HCV direct-acting antiviral agents elbasvir/grazoprevir and the HIV integrase inhibitors raltegravir and dolutegravir.
J Antimicrob Chemother
; 74(3): 710-717, 2019 03 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-30541077
13.
Efficacy and safety of ruzasvir 60 mg and uprifosbuvir 450 mg for 12 weeks in adults with chronic hepatitis C virus genotype 1, 2, 3, 4 or 6 infection.
J Viral Hepat
; 26(6): 675-684, 2019 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-30739366
14.
Pharmacokinetics of elbasvir and grazoprevir in subjects with end-stage renal disease or severe renal impairment.
Eur J Clin Pharmacol
; 75(5): 665-675, 2019 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-30680407
15.
Characterisation of the absorption, distribution, metabolism, excretion and mass balance of doravirine, a non-nucleoside reverse transcriptase inhibitor in humans.
Xenobiotica
; 49(4): 422-432, 2019 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-29557716
16.
Intrapulmonary Pharmacokinetics of Relebactam, a Novel ß-Lactamase Inhibitor, Dosed in Combination with Imipenem-Cilastatin in Healthy Subjects.
Antimicrob Agents Chemother
; 62(3)2018 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-29311084
17.
Pharmacokinetics, Safety, and Tolerability of Single and Multiple Doses of Relebactam, a ß-Lactamase Inhibitor, in Combination with Imipenem and Cilastatin in Healthy Participants.
Antimicrob Agents Chemother
; 62(9)2018 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-29914955
18.
Grazoprevir, ruzasvir, and uprifosbuvir for hepatitis C virus after NS5A treatment failure.
Hepatology
; 66(6): 1794-1804, 2017 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-28688129
19.
Effect of Hepatic Impairment on the Pharmacokinetics of Grazoprevir, a Hepatitis C Virus Protease Inhibitor.
Antimicrob Agents Chemother
; 61(12)2017 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-28947470
20.
No clinically meaningful pharmacokinetic interaction between the hepatitis C virus inhibitors elbasvir and grazoprevir and the oral contraceptives ethinyl estradiol and levonorgestrel.
Eur J Clin Pharmacol
; 73(5): 593-600, 2017 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-28233047